Form 4: Nurix Therapeutics Director Receives Stock Option Grant

Director David L. Lacey was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director David L. Lacey received a grant of 31,250 stock options for Nurix Therapeutics, Inc. (NRIX) common stock.
• The options have an exercise price of $15.86 per share.
• The grant date is May 15, 2026, with an expiration date of May 14, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is subject to market volatility and the future performance of NRIX stock.

Future Outlook

The options vest 100% on the earlier of the next annual meeting of stockholders or May 15, 2027, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 15, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Form 4, Stock Options, Insider Trading, Director Compensation